Accuracy of sentinel lymph node biopsy in male breast cancer: Systematic review and meta-analysis.

Accuracy False-negative rate Identification rate Male breast cancer Meta-analysis Sentinel lymph node biopsy Systematic review

Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
05 Mar 2024
Historique:
received: 21 11 2023
revised: 25 02 2024
accepted: 27 02 2024
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 10 3 2024
Statut: aheadofprint

Résumé

Sentinel lymph node biopsy (SLNB) is commonly used in the surgical management of male breast cancer. Contrary to female breast cancer, limited data exist about its performance in male breast cancer. The objective of this systematic review and meta-analysis was to evaluate the SLNB accuracy in male breast cancer. MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from January 1995 to April 2023 for studies evaluating the SLNB identification rate and false-negative rate in male breast cancer with negative preoperative axillary evaluation and primary surgery. For SLNB false-negative rate, the gold standard was the histology of axillary lymph node dissection (ALDN). Methodological quality was assessed by using the QUADAS-2 tool. Pooled estimates of the SLNB identification rate and false-negative rate were calculated. Heterogeneity of the pooled studies was evaluated using I A total of 12 retrospective studies were included. The 12 studies that reported the SLNB identification rate gathered a total of 164 patients; the 5 studies that reported the SLNB false-negative rate gathered a total of 50 patients with a systematic ALND. The pooled estimate of the SLNB identification rate was 99.0%. The SLNB false-negative rates were 0% in the 5 included studies and consequently so as the pooled estimate of the false-negative rate with no heterogeneity. SLNB for male breast cancer, following negative preoperative axillary assessment and primary surgery, appears feasible, consistent, and effective. Our research supports conducting immediate SLNB histological evaluation to facilitate prompt ALND in case of positive results.

Sections du résumé

BACKGROUND BACKGROUND
Sentinel lymph node biopsy (SLNB) is commonly used in the surgical management of male breast cancer. Contrary to female breast cancer, limited data exist about its performance in male breast cancer. The objective of this systematic review and meta-analysis was to evaluate the SLNB accuracy in male breast cancer.
METHODS METHODS
MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from January 1995 to April 2023 for studies evaluating the SLNB identification rate and false-negative rate in male breast cancer with negative preoperative axillary evaluation and primary surgery. For SLNB false-negative rate, the gold standard was the histology of axillary lymph node dissection (ALDN). Methodological quality was assessed by using the QUADAS-2 tool. Pooled estimates of the SLNB identification rate and false-negative rate were calculated. Heterogeneity of the pooled studies was evaluated using I
RESULTS RESULTS
A total of 12 retrospective studies were included. The 12 studies that reported the SLNB identification rate gathered a total of 164 patients; the 5 studies that reported the SLNB false-negative rate gathered a total of 50 patients with a systematic ALND. The pooled estimate of the SLNB identification rate was 99.0%. The SLNB false-negative rates were 0% in the 5 included studies and consequently so as the pooled estimate of the false-negative rate with no heterogeneity.
CONCLUSION CONCLUSIONS
SLNB for male breast cancer, following negative preoperative axillary assessment and primary surgery, appears feasible, consistent, and effective. Our research supports conducting immediate SLNB histological evaluation to facilitate prompt ALND in case of positive results.

Identifiants

DOI: 10.1016/j.breast.2024.103703 PMID: 38461570
pubmed: 38461570
pii: S0960-9776(24)00034-1
doi: 10.1016/j.breast.2024.103703
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103703

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Guillaume Parpex (G)

Paris Cité University, Paris, France; Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France. Electronic address: guillaume.parpex@aphp.fr.

Marie Ottaviani (M)

Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Henri Lorphelin (H)

Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Matthieu Mezzadri (M)

Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Eva Marchand (E)

Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Laurence Cahen-Doidy (L)

Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Jean Louis Benifla (JL)

Paris Cité University, Paris, France; Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Cyrille Huchon (C)

Paris Cité University, Paris, France; Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Camille Mimoun (C)

Paris Cité University, Paris, France; Department of Gynecology and Obstetrics, Breast Surgery Department, APHP, Lariboisière Hospital, Saint Louis Hospital, Paris, France.

Classifications MeSH